Study of Occipital Nerve Stimulation for Drug Refractory Migraine (PRISM UK)
A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Occipital Nerve Stimulation for Drug Refractory Migraine
Sponsor: Boston Scientific Corporation
Terminated
Sponsor closed enrollment early based on interim data from the PRISM US Pivotal Study.
Other terminated trials from Boston Scientific Corporation
- Atrial Fibrillation Paroxysmal · Phase NA · Nov 2025
- Benign Prostatic Hyperplasia · Phase NA · Jul 2025
- Varicose Veins · Phase PHASE4 · Apr 2024
- Benign Biliary Strictures With Current or Prior Biliary Obstruction · Phase PHASE4 · Feb 2024
- Heart Failure NYHA Class II · Oct 2023
More terminations from Boston Scientific Corporation
Listed as NCT00747812, this PHASE2 trial focuses on Migraine and remains terminated or withdrawn. Sponsored by Boston Scientific Corporation, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Dec 2020 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
May 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Scientific Corporation
For direct contact, visit the study record on ClinicalTrials.gov .